** Drugmaker GlaxoSmithKline down 3 percent, hit by trading ex-dividend and downgrade to "neutral" from "buy" by brokerage UBS ** UBS analyst Alexandra Hauber says GSK's 2020 pharma outlook implies a sharp deterioration of pharma profit margin, excluding the HIV business ViiV, with ViiV blo
Read moreBy Kate Kelland LONDON, May 14 (Reuters) - Companies that develop new antibiotics should be awarded prize money of up to $3.5 billion for each new drug, instead of selling the medication at a profit, a review backed by Britain's government said on Thursday. The review, lead by former
Read moreBHP Billiton: Credit Suisse reiterates underperform and 1,400p target, UBS stays at buy with 1,625p target. Experian: Nomura reiterates buy and nudges target higher to 1,265p from 1,230p, Exane BNP keeps at neutral with 1,200p target. Talk Talk: UBS hikes target to 350p from 300p and reiterates neu
Read more* Guinea and Sierra Leone report 9 cases in past week * GSK, NewLink vaccine trials may not produce efficacy data * WHO hopes for framework deal on Ebola R&D by year-end By Stephanie Nebehay GENEVA, May 12 (Reuters) - With Ebola nearly stamped out in West Africa, vaccine t
Read moreRBS: Credit Suisse reiterates underperform and 320p target. GlaxoSmithKline: Deutsche reiterates hold and lowers target to 1,540p from 1,600p. HSBC: Exane BNP reiterates underperform and 600p target. Lloyds: Credit Suisse reiterates neutral and 72p target. Sage Group: Goldman Sachs reiterates neu
Read more